Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Inmune Bio ( (INMB) ).
On September 29, 2025, INmune Bio Inc. announced the submission of a manuscript to npj Dementia detailing the results of its Phase 2 MINDFuL trial. The trial evaluated the safety and efficacy of XPro™ in early Alzheimer’s disease patients with inflammation. Although the primary endpoint was not met in the overall population, promising results were observed in a subgroup with amyloid pathology and high inflammatory burden. The findings suggest potential therapeutic benefits of XPro™ and its favorable safety profile, supporting its continued development as a precision medicine approach. The absence of amyloid-related imaging abnormalities in high-risk patients further distinguishes XPro™ from other treatments, indicating potential for broader use.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company operates three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, CORDStrom™, and INKmune®, which are involved in various stages of clinical trials for conditions like Alzheimer’s disease, recessive dystrophic epidermolysis bullosa, and metastatic castration-resistant prostate cancer.
Average Trading Volume: 1,887,608
Technical Sentiment Signal: Sell
Current Market Cap: $56.09M
For a thorough assessment of INMB stock, go to TipRanks’ Stock Analysis page.